Data on vildagliptin and vildagliptin plus metformin combination in type-2 diabetes mellitus management

Sambit Das¹, A K Gupta², Biplab Bandyopadhyaya³, B Harish Darla⁴, Vivek Arya⁵, Mahesh Abhyankar⁶*, Santosh Revankar⁶

¹Endeavour Clinics, Bhubaneswar, India; ²Rahas Medical Store Hospital, Lucknow, India; ³Thyroid, Diabetes & Hormone Care, Indore, India; ⁴Darla’s Healthcare, Mysore, India; ⁵Center for Endocrine and Diabetes, Ahmedabad, India; ⁶USV Pvt. Ltd., Mumbai, India;

Corresponding author* Dr. Mahesh Abhyankar Email: dr.mabhyankar@gmail.com

Received February 28, 2021; Revised March 15, 2021; Accepted March 18, 2021, Published March 31, 2021
DOI: 10.6026/97320630017413

Declaration on official E-mail:
The corresponding author declares that official e-mail from their institution is not available for all authors

Declaration on Publication Ethics:
The authors state that they adhere with COPE guidelines on publishing ethics as described elsewhere at https://publicationethics.org/. The authors also undertake that they are not associated with any other third party (governmental or non-governmental agencies) linking with any form of unethical issues connecting to this publication. The authors also declare that they are not withholding any information that is misleading to the publisher in regard to this article.

Abstract:
It is of interest to evaluate the clinical effectiveness and safety of vildagliptin as monotherapy and combination therapy of vildagliptin and metformin for the management of type 2 diabetes mellitus (T2DM) patients in Indian settings. The study included patients with T2DM (aged >18 years) receiving vildagliptin monotherapy and vildagliptin in combination with metformin therapy of various strengths. Data related to demographics, risk factors, medical history, glycated hemoglobin (HbA1c) levels, and medical therapies were retrieved from medical records. Out of 9678 patients (median age, 52.0 years), 59.1% were men. A combination of vildagliptin and metformin (50/500 mg) was the most commonly used therapy (54.8%), and the median duration of therapy was 24.0 months. The predominant reason for selecting vildagliptin therapy was to improve HbA1c levels (87.8%). A total of 87.5% of patients required dosage up-titration. Vildagliptin therapy was used in patients with T2DM and associated complications (peripheral neuropathy, CAD, nephropathy, retinopathy, autonomous neuropathy, stroke/TIA, and peripheral artery disease). Among 5175 patients who experienced body weight changes, a majority of patients showed a loss of weight (68.6%). The target glycemic control was achieved in 95.3% of patients. The mean HbA1c levels were significantly decreased post-treatment (mean change: 1.34%; p<0.001). Adverse events were reported in 0.4% of patients. Physicians rated the majority of patients as good to excellent on the global evaluation of efficacy and tolerability scale (98.9%, each). Vildagliptin as monotherapy and combination therapy of vildagliptin and metformin was an effective therapy in reducing HbA1c helps in achieving target glycemic control, and was well tolerated in Indian patients with T2DM continuum.

Keywords: Antidiabetic therapy, DPP4i, glycemic control, hypertension.
Background:
The poor glycemic control, long duration of illness, and the ethnicity of the population contribute to the increased susceptibility to diabetes associated complications [1]. Indian individuals with T2DM are highly susceptible to the risk of developing macrovascular complications with a 40% higher risk of mortality due to cardiovascular diseases, as compared to the White populations [2-4]. Moreover, the prevalence of comorbidities in Indian patients with diabetes is high along with peripheral vascular disease, hypertension, ocular diseases, and dyslipidemia as the most common comorbidities [5-8]. Therefore, early diagnosis of diabetes and improved glycemic control will aid in alleviating the risk factors of these patients. The American Diabetes Association (ADA), the European Association for the Study of Diabetes (EASD), and the India-specific diabetes management guidelines recommend the use of metformin along with lifestyle changes as first-line therapy for diabetes management [9-11]. Targeted glycemic levels may not be achieved by metformin or other oral antidiabetic drugs (OADs) monotherapy. Hence, considering diabetes as a progressive disease, combination therapies of metformin with other oral antidiabetic drugs (OADs) are recommended [9-11]. Moreover, if patients fail to achieve target glycemic levels with monotherapy, the combination therapies of metformin with other OADs and/or insulin are recommended [9-11]. Vildagliptin is a second-generation dipeptidyl peptidase-4 (DPP-4) inhibitor [12] and evidence suggests potential mechanisms of synergy between metformin and vildagliptin [13, 14]. The clinical efficacy and safety of vildagliptin monotherapy or in combination with metformin have been demonstrated in several studies. Globally, the effectiveness, tolerability, and low discontinuation rates of vildagliptin monotherapy and combination therapy of vildagliptin and metformin are reported in several real-world studies [15-17]. However, there is a need for evidence from India demonstrating the overall clinical benefits of glycemic control and weight reduction with vildagliptin monotherapy [18] or vildagliptin and metformin combination therapy for diabetes [19, 20]. Therefore, it is of interest to document the treatment patterns, clinical effectiveness, and safety profile of vildagliptin monotherapy, vildagliptin, and metformin combination therapy for the management of the T2DM continuum in India.

Methods:
This retrospective, multi-centric, observational real-world study was conducted across 365 Indian healthcare centers having medical records of adult patients with T2DM who had received vildagliptin alone or as an add-on to metformin therapy. The study was conducted in accordance with the ethical principles that are consistent with the Declaration of Helsinki, International Conference on Harmonization-Good Clinical Practices, and the applicable legislation on non-interventional studies. Approval for the study protocol from an Independent Ethics Committee was obtained before the study initiation.

Study population
Patients of either sex, aged >18 years and who had received vildagliptin monotherapy or fixed-dose combination of vildagliptin and metformin (IR-Immediate Release) for the treatment of T2DM were identified. The patients’ treatment information was sourced from the treating physician under an agreement. Patients having incomplete data files were excluded from the study. According to the investigator’s discretion, unsuitable patients or patient data were also not included in the study.

Outcomes
The study outcomes included the evaluation of change in glycated hemoglobin (HbA1c) levels and weight changes after the treatment with vildagliptin alone or in combination with metformin therapy of various strengths. In addition, demographics of patients receiving vildagliptin alone or in combination with metformin therapy of various strengths, duration of treatment, other OADs and/or insulin and any concomitant medication received during the study period, presence of any concurrent disease and, adverse events reported within past 12 months were assessed.

Statistical analysis
Data were analyzed using Statistical Package for The Social Sciences (SPSS) software, version 23.0. Demographic characteristics were summarized with descriptive statistics including median and interquartile range (IQR) for continuous variables, and frequency and percentages for categorical variables. A comparison of qualitative and quantitative variables between the groups was done using the chi-square test and Mann-Whitney U test, respectively. A p-value <0.05 was considered statistically significant.

Table 1: Patient demographics and treatment related observations.

| Parameters                   | Values (N=9678) |
|------------------------------|-----------------|
| Age (years), [n=9656]        | 52.0 (45.0-61.0) |
| Age group (years), n (%) [n=9656] |                |
| >18-645                      | 2701 (28.0)     |
| >60                          | 2589 (26.6)     |
| Sex, n (%) [n=9422]          |                |
| Men                          | 5568 (59.1)     |
| Women                        | 3854 (40.9)     |
| Locality, n (%) [n=7519]     |                |
| Urban/Semi-urban             | 6263 (83.3)     |
| Rural/Semi-rural             | 1286 (16.7)     |
| Height (cm), [n=9297]        | 163.0 (157.0-169.0) |
| Weight (kg), [n=9574]        | 71.0 (65.0-79.0) |
Concomitant anti-diabetic medications

| Parameters | Values (N=9678) |
|------------|----------------|
| AGIs       | 721 (12.0)     |
| GLP1 agonist | 27 (0.4)     |

Data shown as n (%), unless otherwise specified. AGIs, alpha-glucosidase inhibitors; BD, twice a day; GLP1, glucagon-like peptide-1; IQR, interquartile range; OD, once a day; BD, twice a day; SGLT 2 I, sodium-glucose co-transporter-2 inhibitor. Neuropathic pain included anti-anxiety drugs and non-steroidal anti-inflammatory drugs. Others, patients on concomitant non-diabetic medication including antacids, antibiotics, anticoagulants, anticonvulsants, anti-emetics, antihistamines, anti-malarials, thyroxine, vitamins and multivitamins.

### Table 3: Observations related to weight alterations, glycemic control, and adverse events.

| Parameters | Number of patients (%) |
|------------|------------------------|
| Dose titration of vildagliptin or vildagliptin and metformin combination [n=1969] | |
| Dosage up titration | 1724 (87.5) |
| Dosage down titration | 245 (12.5) |
| HbA1c level before treatment initiation [n=9328] | |
| <7.5 | 795 (8.3) |
| 7.5-8.0 | 2763 (29.6) |
| 8.0-8.5 | 2681 (28.7) |
| 8.5-9.0 | 1460 (15.6) |
| 9.0-9.5 | 835 (9.0) |
| 9.5-10.0 | 462 (5.0) |
| >10.0 | 332 (3.6) |
| Patients with weight changes during the therapy [n=5175] | |
| a) Weight gain (kg) | |
| 0-2 | 1101 (21.3) |
| 2-4 | 455 (8.8) |
| >4 | 68 (1.3) |
| b) Weight loss (kg) | |
| 0-2 | 2638 (50.9) |
| 2-4 | 754 (14.6) |
| >4 | 159 (3.1) |
| Patients achieving the glycemic goal [n=9678] | 9223 (95.3) |
| Number of adverse events reported [n=44] | |
| Gastritis | 9 |
| Dyspepsia | 9 |
| GI disease | 7 |
| Giddiness | 6 |
| Nausea | 2 |
| Diarrhea | 2 |
| Hypoglycemia | 2 |
| Others | 7 |

Data shown as n (%). *N=9678, unless otherwise specified. FPG, fasting plasma glucose; GI, gastrointestinal; HbA1c, glycosylated hemoglobin; PPG, postprandial plasma glucose. Other adverse events include abdominal discomfort and inadequate bowel movement, acidity, and constipation.
The majority of patients (54.8%) enrolled in the study were from the age group of >40 to ≤60 years. The median body mass index (BMI) of the overall population was 27.0 kg/m². The median duration of treatment (months), median (IQR) was 24.0 (12.0-36.0). HbA1c level (%) was documented as follows: before treatment initiation, 8.3 (7.8-9.0) vs. 8.5 (8.0-9.0), p=0.022; after treatment, 7.1 (6.7-7.6) vs. 7.1 (6.6-7.6), p=0.706. Patients with 2TDM were included. The median (IQR) age was 52.0 (45.0-61.0) years and the majority of patients (45.4%) were from the age group of >40 to ≤60 years. The proportion of male patients (59.1%) was higher than female patients (40.9%). The majority of the patients were enrolled in urban and semi-urban areas (83.3%). The median body mass index (BMI) of the overall population was 27.0 kg/m². The median duration of diabetes was 60.0 months. Family history of diabetes (49.4%) and sedentary lifestyle (44.0%) were the most common risk factors observed followed by obesity (37.6%), smoking (29.6%), and emotional stress (26.3%). The most commonly observed comorbidities were hypertension (68.7%) and dyslipidemia (47.1%) while peripheral neuropathy (44.6%) and coronary artery disease (CAD) (30.6%) were the most common complications observed in the study patients (Table 1). The majority of patients (54.8%)...
received a combination of vildagliptin and metformin (50/500 mg) while 23.7% received vildagliptin monotherapy (50 mg), 15.1% received a combination of vildagliptin and metformin (50/1000 mg) and 6.4% received combination of vildagliptin and metformin (50/850 mg). Vildagliptin as monotherapy or combination therapy with metformin was used across a wide range of age groups from younger patients aged >18 years to elderly patients aged >60 years. Vildagliptin alone or in combination with metformin twice daily (BD) was the most frequently used dosage pattern (74.1%). The median duration of treatment (vildagliptin alone or in combination with metformin therapy) was 24.0 months (Table 2). A majority of patients (94.7%) received sulfonylureas as the concomitant anti-diabetic medication. Insulin was administered to 944 (15.7%) patients. Among the concomitant non-diabetic medications, antihypertensives (60.4%) were the most common class of drugs followed by statins (31.6%) (Table 2). The analysis revealed that the most common reason for selecting vildagliptin alone or in combination with metformin was to achieve an improvement in HbA1c levels (87.8%). Other common reasons included the control of fasting plasma glucose (45.4%) and postprandial plasma glucose (35.2%), low risk of hypoglycemia (49.8%), and weight neutrality (34.2%) (Figure 1). A total of 1969 patients required dosage titration during the treatment, the majority of them (87.5%) required dosage up-titration (Table 3). The most common reason given for titration was to improve HbA1c level (78.7%) as shown in Figure 1. Before initiating the treatment, a total of 91.5% of patients were having poor glycemic control (HbA1c ≥7.5%) where 29.6% and 28.7% of the patients were having HbA1c levels in the range of 7.5-8.0% and 8.0-8.5%, respectively (Table 3). Figure 2A presents the trend of vildagliptin monotherapy and combination therapy of vildagliptin and metformin with respect to HbA1c levels across the study population. The data suggested that the combination therapy of vildagliptin and metformin at 50/500 mg dose and vildagliptin monotherapy at 50 mg dose were the most commonly prescribed therapies in the patient population across a wide range of HbA1c levels from <7.5 to >10%. A total of 95.3% of patients achieved target glycemic control with vildagliptin monotherapy or vildagliptin and metformin combination therapy. The treatment with vildagliptin monotherapy or vildagliptin and metformin combination therapy significantly reduced the mean HbA1c levels by 1.34% [95% CI, 1.31-1.36]; p<0.001 when compared to the pre-treatment levels (8.62% vs. 7.28%) (Figure 2B). A total of 4503 (46.6%) patients experienced no change in body weight during treatment. Among 5175 (53.4%) patients who experienced body weight changes during therapy, majority of them (3551, 68.6%) had lost weight while the remaining 1624 (31.4%) patients had gained weight. Of those who lost weight, more than half (N=2638) had a weight reduction in the range of 0-2 kg (Table 3). A total of 44 patients (0.4%) reported adverse events with gastritis and dyspepsia being the most common adverse events (9, each) (Table 3). Physicians rated the majority of patients as good to excellent on the global evaluation of efficacy and tolerability scale (98.9%, each) (Figure 3).

The median age was significantly higher in patients receiving vildagliptin 50 mg monotherapy (54.0 years) as compared to those receiving vildagliptin and metformin combinations (50/1000, 50/500, and 50/850 mg) (52.0 years, each) (p<0.001). The proportion of patients receiving combination therapy of vildagliptin and metformin 50/850 mg from age group >45-60 years (54.5%) was significantly higher compared to other treatment groups (p<0.001). The median (IQR) duration of diabetes was significantly higher in patients receiving a combination of vildagliptin and metformin 50/1000 mg as compared to those receiving other therapies such as vildagliptin monotherapy 50 mg (60.0 [26.0-96.0] months), vildagliptin and metformin 50/500 mg combination therapy (60.0 [36.0-96.0] months) and vildagliptin and metformin 50/850 mg combination therapy (60.0 [36.0-84.0] months) (p<0.001). Vildagliptin or vildagliptin and metformin combinations were used in patients with T2DM with associated complications, like peripheral neuropathy, CAD, nephropathy, retinopathy, autonomous neuropathy, stroke/TIA, and PAD. In T2DM patients taking vildagliptin or vildagliptin and metformin combination therapy,
the common comorbidity was hypertension and dyslipidemia observed in 64.4% to 71.1% and 45.5% to 50.7%, respectively. Obesity was observed in 42% of patients taking vildagliptin and metformin 50/1000 mg, while 25.1% to 26.3% in other dosage forms. NFALD was observed in 22.2% of the patients taking vildagliptin 50 mg, while 3.4% to 7.2% in other dosage forms (Table 4).

Discussion:
This real-world study documented the clinical characteristics, and treatment patterns including dosage and duration of vildagliptin monotherapy or vildagliptin and metformin combination therapy in adult patients with T2DM across 365 clinical study centers in India. In addition, it also evaluated the effect of vildagliptin therapy on glycemic control and the safety profile of patients with the T2DM continuum. A majority of the patients were from urban areas and were middle-aged with a median age of 52.0 years. A high prevalence of disease in male patients, family history of diabetes, sedentary lifestyle, and obesity were the most commonly observed risk factors of T2DM in the present study. These findings are in line with previous Indian studies. According to the Indian Council of Medical Research–India Diabetes (ICMR-INDIAB) study, age, male sex, obesity, hypertension, and family history of diabetes were the independent risk factors for diabetes in both urban and rural areas. The study also reported a higher prevalence of diabetes in urban areas, especially among low socioeconomic groups [21]. Similarly, a recent 10-year prospective cohort study from Southern India reported that age >45 years, family history of T2DM, BMI ≥25 kg/m², and presence of obesity as the risk factors for T2DM [22]. The presence of comorbidities in Indian patients with T2DM is well established in several previous studies [5-8]. Uncontrolled glycemia and chronic diabetes substantially contribute to the elevated risk of
suggested that monotherapy of vildagliptin or combination therapy therefore, the most commonly prescribed concomitant medications included patients with hypertension and dyslipidemia, and dyslipidemia along with diabetes. Similarly, the present study also included patients who had comorbidities such as hypertension and diabetes. Vildagliptin with or without metformin was an effective therapy in reducing HbA1c and greater reduction in the body weight. More than 90% of the patients had uncontrolled glycemic levels before treatment and good glycemic control achieved by 95.3% of patients after the treatment. These observations support the clinical effectiveness of vildagliptin monotherapy or vildagliptin and metformin combination therapy in achieving glycemic control and weight neutralization. A meta-analysis of 58 randomized controlled trials, DPP4-inhibitors, vildagliptin 50 mg BD, and linagliptin 10 mg QD, suggested a significant lowering effect on the glycemic indices in comparison to the placebo [30]. The 5-year long trial results suggest early intervention with vildagliptin plus metformin provides significant continuing benefits compared to the initial metformin monotherapy used for patients with newly diagnosed T2DM [31]. In the post-hoc analysis of an observational real-world EDGE study, Wangnoo et al. assessed the safety and efficacy of vildagliptin in combination with another OAD in 11,057 Indian patients with T2DM. Vildagliptin and metformin combination was used in more than 70% of the study population. The HbA1c reduction was in favor of vildagliptin usage, achieved in 68.5% in the vildagliptin cohort compared to the comparator cohort (56.8%), with an unadjusted OR of 1.65 (95% CI: 1.53, 1.79; p < 0.0001) [18]. In previous studies, vildagliptin or vildagliptin and metformin combination therapy was well tolerated [18, 31]. These findings are in line with the current study results that have shown a smaller number of patients experiencing adverse events with these treatments. Physicians' global evaluation of efficacy and tolerability showed a majority of patients on a good to excellent scale (98.9%). Evidence from Indian literature suggests that, of all the combination of OADs, the combination of metformin and vildagliptin was prescribed by the majority of the physicians [27, 32]. These observations support the use of vildagliptin as an add-on therapy to metformin and are the preferred choice of therapy by physicians in Indian settings. The present study has several limitations. Due to the retrospective nature of this study, several parameters such as the antidiabetic regimens used before vildagliptin or vildagliptin/metformin combination therapy and time of the previous visit could not be captured, which may have an indirect effect on the overall study results.

**Conclusion:**

Vildagliptin with or without metformin was an effective therapy in reducing HbA1c that helped in achieving target glycemic control and was well tolerated in Indian patients with the T2DM continuum. The use of vildagliptin therapy in patients with comorbidities (hypertension and dyslipidemia), complications (peripheral neuropathy, CAD, nephropathy, and retinopathy), different age groups (younger to elderly patients), and physician diabetes-associated complications. Therefore, comorbidities such as hypertension and dyslipidemia, and other complications pose a high risk of mortality for the Indian cohort of T2DM. A high prevalence of hypertension was observed in the present study population. The results corroborate with the observations from several other Indian studies reported that 20%-40% of patients have both diabetes and hypertension [22-24]. A joint consensus statement from the American and European Diabetes Associations recommends that DPP-4 inhibitor may be used if there is a need to avoid hypoglycemia or control the weight gain [10]. The use of vildagliptin has been approved in Indian patients for the treatment of T2DM as monotherapy or in combination with metformin, sulfonylureas, and thiazolidinediones, as well as with insulin [20]. In India, vildagliptin and metformin combination tablets are available in 50/500 mg, 50/850 mg, and 50/1000 mg doses [20]. The most commonly used therapy in the present study was the combination therapy of vildagliptin and metformin at 50/500 mg dose followed by vildagliptin monotherapy at 50 mg dose. Several real-world studies from India have reported the use of vildagliptin monotherapy (4%-18%) [25, 26] and vildagliptin and metformin combination therapy (37%) [27] for the management of T2DM. About 70% of the present study cohort used the twice-daily formulation. In the present study, the use of vildagliptin either as monotherapy or combination therapy with metformin across a wide range of age groups (>18 years to >60 years) suggests the benefits of vildagliptin to a patient population of both younger and elder age groups. More than one-third of the patient population on vildagliptin therapy presented CAD as a complication. However, a meta-analysis of 17000 patients has provided evidence that supports the cardiovascular safety of vildagliptin [28]. Similarly, a real-world study by Williams et al. suggested that exposure to vildagliptin was not associated with an increased overall CVD risk or risk of myocardial infarction, acute coronary syndrome, stroke, and congestive heart failure when compared with other OADs [29]. In the present study, more than 70% of patients received concomitant anti-diabetic medications. Sulfonylureas were the most commonly prescribed anti-diabetic medications along with vildagliptin or vildagliptin and metformin combination therapies. A Japanese study reported that sulfonylurea (26.3%) was the second most commonly prescribed anti-diabetic drug after biguanide (54.6%) in patients with T2DM receiving vildagliptin monotherapy [17]. Several population-based studies in India have included patients who had comorbidities such as hypertension and dyslipidemia along with diabetes. Similarly, the present study also included patients with hypertension and dyslipidemia, and therefore, the most commonly prescribed concomitant medications were antihypertensives and statins [16, 20]. The present study suggested that monotherapy of vildagliptin or combination therapy with metformin showed greater improvements in the mean HbA1c and greater reduction in the body weight. More than 90% of the patients had uncontrolled glycemic levels before treatment and good glycemic control achieved by 95.3% of patients after the treatment. These observations suggest the clinical effectiveness of vildagliptin monotherapy or vildagliptin and metformin combination therapy in achieving glycemic control and weight neutralization. A meta-analysis of 58 randomized controlled trials, DPP4-inhibitors, vildagliptin 50 mg BD, and linagliptin 10 mg QD, suggested a significant lowering effect on the glycemic indices in comparison to the placebo [30]. The 5-year long trial results suggest early intervention with vildagliptin plus metformin provides significant continuing benefits compared to the initial metformin monotherapy used for patients with newly diagnosed T2DM [31]. In the post-hoc analysis of an observational real-world EDGE study, Wangnoo et al. assessed the safety and efficacy of vildagliptin in combination with another OAD in 11,057 Indian patients with T2DM. Vildagliptin and metformin combination was used in more than 70% of the study population. The HbA1c reduction was in favor of vildagliptin usage, achieved in 68.5% in the vildagliptin cohort compared to the comparator cohort (56.8%), with an unadjusted OR of 1.65 (95% CI: 1.53, 1.79; p < 0.0001) [18]. In previous studies, vildagliptin or vildagliptin and metformin combination therapy was well tolerated [18, 31]. These findings are in line with the current study results that have shown a smaller number of patients experiencing adverse events with these treatments. Physicians' global evaluation of efficacy and tolerability showed a majority of patients on a good to excellent scale (98.9%). Evidence from Indian literature suggests that, of all the combination of OADs, the combination of metformin and vildagliptin was prescribed by the majority of the physicians [27, 32]. These observations support the use of vildagliptin as an add-on therapy to metformin and are the preferred choice of therapy by physicians in Indian settings. The present study has several limitations. Due to the retrospective nature of this study, several parameters such as the antidiabetic regimens used before vildagliptin or vildagliptin/metformin combination therapy and time of the previous visit could not be captured, which may have an indirect effect on the overall study results.

**Conclusion:**

Vildagliptin with or without metformin was an effective therapy in reducing HbA1c that helped in achieving target glycemic control and was well tolerated in Indian patients with the T2DM continuum. The use of vildagliptin therapy in patients with comorbidities (hypertension and dyslipidemia), complications (peripheral neuropathy, CAD, nephropathy, and retinopathy), different age groups (younger to elderly patients), and physician
acceptance suggests wide use of vildagliptin for each subgroup of the diabetic continuum in Indian settings.

Acknowledgments:
We acknowledge Ms. Farida Hussain, Ms. Monal Patil, Mr. Smitabrat Das Gupta, and Ms. Annsusan Renji from USV Pvt Ltd for their assistance in carrying out the project. The medical writing support was provided by Dr. Sona Warrier from the scientific services team of USV Pvt Ltd and Ms. Snehal Khanolkar from S qa r o n a M e d i c a l C o m m u n i c a t i o n s LLP (Mumbai). We acknowledge BioQuest Solutions Private Limited for their services in the conduction of the real-world study.

Contributors:
Dr. A Muthukumar, Dr. A Paneerselvam, Dr. A Premkumar, Dr. A Senthuramankaran, Dr. A Shanmugam, Dr. Abdul Gaffar Hannan, Dr. Abhay Raut, Dr. Ajay Gupta, Dr. Ajay Kumar Patwari, Dr. Ajay V Kaduskar, Dr. Akhilesh Kumar Patel, Dr. Alok Joshi, Dr. Alok Kumar Gupta, Dr. Amit Kumar Mandal, Dr. Ananthakrishnan C, Dr. Animesh Maiti, Dr. Anirban Biswas, Dr. Aniruddha Ghorai, Dr. Anish Ahamed K M, Dr. Anoop Kumar Prasad, Dr. Animesh Chaudhary, Dr. Animesh Chauhan, Dr. Annirudh Singh, Dr. Anurag Goswami, Dr. Anup Kumar Vignesh, Dr. Anuradha Mal Khatod, Dr. Jitendra Patel, Dr. Joe George, Dr. K Arun Karthik, Dr. K Jayaram Reddy, Dr. K Madhukumar, Dr. K Nagesh, Dr. K Prasanna Kumar, Dr. K Premkumar, Dr. K Satyanarayana Reddy, Dr. K V Sathyanarayana Sa, Dr. K Venkataramanan, Dr. K Venugopala Reddy, Dr. Kaizar Dohadwala, Dr. Kalinga B E, Dr. Karra Hanumantha Reddy, Dr. Krishna Kumar, Dr. Krishnapoori Polakulath, Dr. L Meenakshi Sundram, Dr. L Vasanthkannan, Dr. Lalitha Shivaprakash, Dr. Lokesh Abrol, Dr. M A Karmur, Dr. M Jaiga n esh, Dr. M Loganathan, Dr. M Malleswara Rao, Dr. M Prabhu Rami Reddy, Dr. M R Ramakrishna, Dr. M Shunmugavelu, Dr. M Sudhakar, Dr. Mahesh D M, Dr. Manish Chhaganal Sachdev, Dr. Manish Desai, Dr. Manju Sivaraj, Dr. Manjunath Anakal, Dr. Manmohan Sharma, Dr. Manoj Kumar Dash, Dr. Manoj Pandey, Dr. M D Athaullah, Dr. Mehern Prasad Y D, Dr. Mohammad Kamran Khan, Dr. Mohammed Ishaaq Ahmed, Dr. Mohan G, Dr. Mohd Najeeb Anwar, Dr. Mohit Kumar Santra, Dr. Mrinal Kanti Guha, Dr. Mudit Sabharwal, Dr. Mukesh Kumar Gupta, Dr. Mukesh Mehra, Dr. N Narendra Prasad, Dr. N Panchal Roy, Dr. N Prakash, Dr. Namit Akhter Khan, Dr. Nagabhusan Parvateni, Dr. Nagendar Reddy J, Dr. Nagesh M, Dr. Narenda B S, Dr. Naveen Angadi, Dr. Navneet Agrawal, Dr. Nileshkumar M Detroja, Dr. Nirav Navi Tana, Dr. Nishant Gupta, Dr. Niteen C Shetye, Dr. Nitinagarwal, Dr. Nitin Subrav Gade, Dr. P G Sunil Kumar, Dr. P Indrasen Reddy, Dr. P Marchwin Kingston Samuel, Dr. P Selvapandian, Dr. P Sreenivasulu, Dr. Pankaj Aneja, Dr. Pankaj Jain, Dr. Parames S, Dr. Parikshit Goswami, Dr. Pawan Agarwal, Dr. Peeyush Kumar Gupta, Dr. Piyush Desai, Dr. Prabir Kumar Kundu, Dr. Prakash Chandra Patra, Dr. Prakash Kumar Prusty, Dr. Pramod Agarwal, Dr. Pramod G Hiremath, Dr. Prasanta Kumar Mishra, Dr. Prashant Ulhas Kaduskar, Dr. Pratap Kumar Mishra, Dr. Pratul Priyadarshi, Dr. Praveen Kumar Devarthbhavi, Dr. Praveen R Badri, Dr. Preetam B, Dr. Prem Kumar, Dr. Punit Arora, Dr. R Balakrishnan, Dr. R Bharath, Dr. R H Lakshmi, Dr. R Thirumurugan, Dr. Rajendra K D, Dr. Rajendran Prasad, Dr. Rajesh Kumar Marya, Dr. Rajesh Prasad Chaubey, Dr. Rajib Gayan, Dr. Rajmohan, Dr. Ramesh Saxena, Dr. Raju A Gopal, Dr. Ramadoss K, Dr. Ramesh Goyal, Dr. Ramkumar Viswanathan, Dr. Ravi Kumar Padala, Dr. Ravikumar Malladad, Dr. Ravikumar Y S, Dr. Ravindra H S, Dr. Rohan N Patel, Dr. Rohan V Ainchwar, Dr. Rohit Kapoor, Dr. S Dhileepan, Dr. S G Harish, Dr. S K Mathur, Dr. S Murthy, Dr. S
Nallaperumal, Dr. S P Sathish Kumar, Dr. S R Panchamukhi, Dr. S Ramkumar, Dr. S S Lakshmanan, Dr. S Sahubar Sadiq, Dr. S Satyanarayana Murthy, Dr. S Sukumar, Dr. S V Iraniaravan, Dr. Sabeer T K, Dr. Saini Venkateswarlu, Dr. Salil Kumar Pal, Dr. Sandeep Sudhakaran, Dr. Sandeep Suri, Dr. Sanjay Kumar H V, Dr. Sanjay Kishor, Dr. Sanjay More, Dr. Sanjay Raina, Dr. Sanjay Somappa Neeralagi, Dr. Sanjeev Gulati, Dr. Sarfaraj Majid, Dr. Sasikumar V, Dr. Satish Raikar, Dr. Satti S Siddhanta, Dr. Sepuri Krishna Mohan, Dr. Shahnaz Ahmad Mir, Dr. Shailendra Kumar Singh, Dr. Shameer C Sulaiman, Dr. Shankar Kumar V, Dr. Sharan R Pawadshettar, Dr. Shivanand B Boodhal, Dr. Shravan Kumar Ankathi, Dr. Shrinivasa Ashok Patil, Dr. Shweta Bhandari, Dr. Sidduri Srinivas, Dr. Soupayan Dutta, Dr. Sri Krishna Mundhra, Dr. Subodh Banzal, Dr. Subodh Jain, Dr. Subrata Bhattacharyya, Dr. Sudeep Putta Manohar, Dr. Sudesh Singhal, Dr. Sudhager G K S, Dr. Sudhi Ranjan Pattanaik, Dr. Sujit Bhattacharya, Dr. Suman Kirti, Dr. Sunil Dhand, Dr. Sunil Kumar, Dr. Suresh S Sawardekar, Dr. Swapnil Jain, Dr. T Karthikeyan, Dr. T Palaniappan, Dr. T R Sivagnanam, Dr. Thushanth Thomas, Dr. Tirthankar Mukerjee, Dr. U B Padmanaban, Dr. Uday Subhas Bande, Dr. Umesh Chandra Prajapati, Dr. Ummedisetty Rajanikanth, Dr. Utkal Kishore Khadanga, Dr. V Mahadevan, Dr. V Ramakrishna Rao, Dr. V Ramasamy, Dr. V Ravindranath, Dr. V Sreekanth Reddy, Dr. V Venkata Rama Kumar, Dr. Vasudeo H Kripalani, Dr. Veerendra Singh, Dr. Verinder Kumar, Dr. Vijay Kumar K Chaini, Dr. Vijaya Maitri, Dr. Vikas Aggarwal, Dr. Vikram B Kolhari, Dr. Vikrant B Ghatnatti, Dr. Vinay M Dipali, Dr. Vinayswami P M, Dr. Vineet Sabharwal, Dr. Vinod M Vijan, Dr. Viswanath Parsewar, Dr. Yarramsetty Sanjeeva, Lakshmana Rao, Dr. Yatin Gadgil

Funding: This project has been funded by USV Pvt Ltd.

Authorship: All named authors take the responsibility for this integrity of the work as a whole and have given their approval for this version to be published. The study was conducted under ethical guidelines. The contents published herein represent the views and opinions of the various contributing authors and does not necessarily represent the views or opinion of USV Pvt Ltd and/or its affiliates. The details published herein are intended for the dissemination of information for educational, academic, and/or research purposes and are not intended as a substitute for professional medical advice, diagnostic or treatment.

Conflict of interest: There are no conflicts of interest. Dr. Mahesh Abhyankar and Dr. Santosh Revankar are employees of USV Pvt Ltd.

Abbreviations:
FPG: Fasting plasma glucose
HbA1c: Glycosylated hemoglobin
PPG: Postprandial plasma glucose

References:
[1] Unnikrishnan R et al. Nat Rev Endocrinol 2016 12:357. [PMID: 27080137]
[2] Ali MK et al. Indian J Med Res 2010 132:584. [PMID: 21150011]
[3] Mohan V et al. J Diabetes Sci Technol 2010 4:158. [PMID: 20167181]
[4] Forouhi NG et al. Diabetologia 2006 49:2580. [PMID: 16972045]
[5] Podder V et al. J Neurosci Rural Pract 2020 11:467. [PMID: 32753814]
[6] Joshi SR Ann Glob Health 2015 81:830. [PMID: 27108150]
[7] Jayakumari C et al. Diabetes Spectr 2020 33:299. [PMID: 33237576]
[8] Venugopal K and Mohammed MZ Chrismed J Health Res 2014 1:223. [https://care.diabetesjournals.org/content/42/Supplemen t_1]
[9] Davies MJ et al. Diabetes Care 2018 41:2669. [PMID: 30291106]
[10] Bajaj S Int J Diabetes Dev Ctries 2017 38:S1. [PMID: 29527102]
[11] Kalra S. J Assoc Physicians India 2011 59:237. [PMID: 21755761]
[12] Lindsay JR et al. Diabet Med 2005 22:654. [PMID: 15842525]
[13] Ahrén B et al. Diabetes Obes Metab 2011 13:193. [PMID: 21205107]
[14] Melzer Cohen C et al. J Diabetes 2018 10:68. [PMID: 28418203]
[15] Chawla M et al. Curr Med Res Opin 2018 34:1605. [PMID: 29764225]
[16] Hayashi T et al. Expert Opin Pharmacother 2020 21:121. [PMID: 31689132]
[17] Wangnoo SK et al. Indian Journal of Clinical Practice. 2013 24:537.
[18] Ved P and Shah S. Indian J Endocrinol Metab 2012 16:S110. [PMID: 22701828]
[19] Chatterjee S et al. J Diabetes Spectr 2014 6:237. [PMID: 23879210]
[20] V Murugan et al. Lancet Diabetes Endocrinol 2017 5:585. [PMID: 28601585]
Articles published in BIOINFORMATION are open for relevant post publication comments and criticisms, which will be published immediately linking to the original article for FREE of cost without open access charges. Comments should be concise, coherent and critical in less than 1000 words.
